Prot# 526F06: A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination with Ribavirin in Subjects with Treatment-Relapsed Chronic Hepatitis C Virus Infection

Project: Research project

Project Details

StatusFinished
Effective start/end date2/20/082/20/11

Funding

  • ZymoGenetics, Inc. (526F06)